A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

406

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

SKB264

IV Infusion

DRUG

Pembrolizumab

IV Infusion

Trial Locations (1)

RECRUITING

Shanghai Oriental Hospital, Shanghai

All Listed Sponsors

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY